Microphysiological systems in the evaluation of hematotoxicities during drug development

Abstract Microphysiological systems are progressively entering the pharmaceutical industry and various systems have already proven to be highly valuable at different stages of the drug development process. The field of hematotoxicity research has so far received only minor attention, even though microphysiological systems might provide key benefits over current assays. In this review, we will highlight the need for more complex human in vitro assays and how emerging technologies such as microphysiological systems present novel solutions for the study of adverse hematologic effects.